Citations

Clear

3 citation(s) found for "Yin, Peng".

Liquid Chromatography–Tandem Mass Spectrometry in Newborn Screening Laboratories
Basheeruddin, Khaja, Burlina, Alberto , Chen, Hsiao-Jan, Dizikes, George J. , Dorley, M. Christine , Giugliani, Roberto , Hietala, Amy, Kao, Shu‐Min, Klug, Tracy, Kubaski, Francyne , Liao, Hsuan-Chieh , Martin, Monica, Manning, Adrienne, Orsini, Joseph J. , Peng, Yin , Ranieri, Enzo , Rohrwasser, Andreas , Szabo‐Fresnais, Nicolas, Turgeon, Coleman , Wang, Liyun , Matern, Dietrich , Burlina, Alberto , Chien, Yin-Hsiu , Dorley, Christine , Giugliani, Roberto , Kubaski, Francyne , Turgeon, Coleman T, Matern, Dietrich , Gelb, Michael H. , Hong, Xinying , Khaledi, Hamid , Vaz, F

Mayo Clinic

International Journal of Neonatal Screening | November 28, 2022 | Volume: 8 | Issue: 4 | Pages: 62

10.3390/ijns8040062 | PMID 36547379 Get It

Tandem mass spectrometry (MS/MS) is the most universal platform currently available for the analysis of enzymatic activities and biomarkers in dried blood spots (DBS) for applications in newborn screening (NBS). Among the MS/MS applications in NBS, the most common is flow-injection analysis (FIA-) MS/MS, where the sample is introduced as a bolus injection into the mass spectrometer without the prior fractionation of analytes. Liquid chromatography combined with MS/MS (LC-MS/MS) has been employed for second-tier tests to reduce the false-positive rate associated with several nonspecific screening markers, beginning two decades ago. More recently, LC-MS/MS has been applied to primary screening for new conditions for which FIA-MS/MS or other methods, including genomic screening, are not yet adequate. In addition to providing a list of the currently used LC-MS/MS-based assays for NBS, the authors share their experience regarding the maintenance requirements of LC-MS/MS vs. FIA-MS/MS systems. The consensus is that the maintenance of LC-MS/MS and FIA-MS/MS instrumentation is similar, and LC-MS/MS has the advantage of allowing for a larger number of diseases to be screened for in a multiplex, cost-effective fashion with a high throughput and an adequate turnaround time.
CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1
Liu, Xin , Mansfield, Aaron S. , Harrington, Susan M. , Li, Yinghua , Yan, Yiyi , Dong, Haidong , Yin, Peng, Yin, Peng, Mansfield, Aaron S , Dong, Haidong

Mayo Clinic

Oncotarget | September 2, 2016 | Volume: 7 | Issue: 43 | Pages: 70223-70231

10.18632/oncotarget.11833 | PMID 27602959 Get It

α 2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction
Peng, Yin, Che, Pulin , Gannon, Mary , Liu, Yin , Li, Ling , Bu, Guojun , Groen, Thomas van , Jiao, Kai , Wang, Qin , Chen, Yunjia , Peng, Yin, Bu, Guojun

Mayo Clinic

Proceedings of the National Academy of Sciences | November 20, 2014 | Volume: 111 | Issue: 48 | Pages: 17296-17301

10.1073/pnas.1409513111 | PMID 25404298 Get It

Significance Endocytic sorting of amyloid precursor protein (APP) governed by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and the generation of amyloid β (Aβ) peptides, the key pathogenic factor of Alzheimer's disease (AD). This study provides the first evidence to our knowledge that a G protein-coupled receptor, namely, the α 2A adrenergic receptor, modulates APP endocytic sorting and promotes Aβ generation through disrupting APP interaction with a Vps10 family protein, sorting-related receptor with A repeat. Significantly, blockade of α 2A AR by a clinical antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting repurposing clinical α 2 AR antagonists as a new direction for AD treatment.